Cargando…

Radiological assessment of effectiveness of soluble RAGE in attenuating Angiotensin II-induced LVH mouse model using in vivo 9.4T MRI

We investigated the effectiveness of soluble Receptor for Advanced Glycation Endproducts (sRAGE) in attenuating angiotensin II (AngII)-induced left ventricular hypertrophy (LVH) using in vivo 9.4T cine-magnetic resonance imaging (CINE-MRI). Mice were divided into four groups: AngII (n = 9), saline (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heo, Dan, Lim, Soyeon, Lee, Jiye, Lee, Myung Eun, Cho, Soyoung, Jeong, Jisu, Seo, Miran, Park, Sungha, Yang, Jaemoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559980/ https://www.ncbi.nlm.nih.gov/pubmed/31186521 http://dx.doi.org/10.1038/s41598-019-44933-6

Ejemplares similares

Soluble RAGE attenuates AngII-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE
por: Jeong, Jisu, et al.
Publicado: (2019)

The Effect of Soluble RAGE on Inhibition of Angiotensin II-Mediated Atherosclerosis in Apolipoprotein E Deficient Mice
por: Lee, Dajeong, et al.
Publicado: (2013)

Retraction: The Effect of Soluble RAGE on Inhibition of Angiotensin II-Mediated Atherosclerosis in Apolipoprotein E Deficient Mice
por: Lee, Dajeong, et al.
Publicado: (2014)

Nelumbo nucifera Receptaculum Extract Suppresses Angiotensin II-Induced Cardiomyocyte Hypertrophy
por: Cho, Soyoung, et al.
Publicado: (2019)

Speckle tracking: distinction of physiologic from pathologic LVH?
por: van der Wall, E. E., et al.
Publicado: (2010)

Fibrosis quantification in Hypertensive Heart Disease with LVH and Non-LVH: Findings from T1 mapping and Contrast-free Cardiac Diffusion-weighted imaging
por: Wu, Lian-Ming, et al.
Publicado: (2017)

Compelling therapy of LVH: straight (and not-so-straight) inferences from evidence
por: Mehta, Ravi Tejraj, et al.
Publicado: (2019)

Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes
por: Humpert, Per M, et al.
Publicado: (2007)

The effect of intensive hemodialysis on LVH regression and blood pressure control in ESRD patients
por: Darabi, Forough, et al.
Publicado: (2020)

ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
por: Kozor, Rebecca, et al.
Publicado: (2016)

Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases
por: Lee, Eun Ji, et al.
Publicado: (2013)

Mouse RAGE Variant 4 Is a Dominant Membrane Receptor that Does Not Shed to Generate Soluble RAGE
por: Peng, Yunqian, et al.
Publicado: (2016)

RAGE ligands stimulate angiotensin II type I receptor (AT1) via RAGE/AT1 complex on the cell membrane
por: Yokoyama, Serina, et al.
Publicado: (2021)

Inhibition of RAGE Attenuates Cigarette Smoke-Induced Lung Epithelial Cell Damage via RAGE-Mediated Nrf2/DAMP Signaling
por: Lee, Hanbyeol, et al.
Publicado: (2018)

Soluble RAGE: a hot new biomarker for the hot joint?
por: Moser, Bernhard, et al.
Publicado: (2005)

Increase of Soluble RAGE in Cerebrospinal Fluid following Subarachnoid Haemorrhage
por: Sokół, Bartosz, et al.
Publicado: (2017)

Soluble Forms of the Receptor for Advanced Glycation Endproducts (RAGE) in Periodontitis
por: Detzen, Laurent, et al.
Publicado: (2019)

Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
por: Marin-Oto, Marta, et al.
Publicado: (2022)

The Mouse-Specific Splice Variant mRAGE_v4 Encodes a Membrane-Bound RAGE That Is Resistant to Shedding and Does Not Contribute to the Production of Soluble RAGE
por: Di Maggio, Stefania, et al.
Publicado: (2016)

Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022)

The association between BMP4 gene polymorphism and its serum level with the incidence of LVH in hypertensive patients
por: Gu, GL, et al.
Publicado: (2015)

Regulation of RAGE for Attenuating Progression of Diabetic Vascular Complications
por: Win, Myat Thu Thu, et al.
Publicado: (2012)

Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients
por: Jung, Eul Sik, et al.
Publicado: (2017)

Integrating CVH and LVH metrics into an optimization strategy for the selection of Iris collimator for Cyberknife Xsight lung tracking treatment
por: Xiao, Feng, et al.
Publicado: (2021)

Experimental renal transplantation in rats improves cardiac dysfunction caused by chronic kidney disease while LVH persists
por: Hagmayer, Linda, et al.
Publicado: (2023)

Overexpression of soluble RAGE in mesenchymal stem cells enhances their immunoregulatory potential for cellular therapy in autoimmune arthritis
por: Park, Min-Jung, et al.
Publicado: (2016)

SUN-LB131 Association of Receptor for Advanced Glycation End Product (RAGE) Gene Polymorphisms & Serum Levels of Soluble RAGE (sRAGE) With Metabolic Syndrome (MS) in Mexican Population
por: Gonzalez-Guerrero, Diana Elizabeth, et al.
Publicado: (2020)

A single high‐fat meal alters human soluble RAGE profiles and PBMC RAGE expression with no effect of prior aerobic exercise
por: Fuller, Kelly N.Z., et al.
Publicado: (2018)

Soluble RAGE and skeletal muscle tissue RAGE expression profiles in lean and obese young adults across differential aerobic exercise intensities
por: Miranda, Edwin R., et al.
Publicado: (2023)

MicroRNA in Diabetic Nephropathy: Renin Angiotensin, AGE/RAGE, and Oxidative Stress Pathway
por: Hagiwara, Shinji, et al.
Publicado: (2013)

2017 ACC/AHA Blood Pressure Classification and Cardiovascular Disease in 15 Million Adults of Age 20–94 Years
por: Lee, Hokyou, et al.
Publicado: (2019)

Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis
por: Narvaez-Rivera, Rodrigo M, et al.
Publicado: (2012)

Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome
por: Zhang, Da-Qi, et al.
Publicado: (2016)

Elevated Plasma Level of Soluble Form of RAGE in Ischemic Stroke Patients with Dementia
por: Tang, Sung-Chun, et al.
Publicado: (2017)

Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs
por: Abdulle, Abdishakur, et al.
Publicado: (2019)

Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells
por: Leung, Sherman S., et al.
Publicado: (2022)

The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges
por: BoonPeng, Hoh, et al.
Publicado: (2013)

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
por: Brown, Alexander J M, et al.
Publicado: (2020)

Assessment of Left Ventricular Hypertrophy (LVH) Criteria by Surface Electrocardiography in a Sample of Iraqi Patients with Systemic Arterial Hypertension
por: Altaweel, Rafid Bashir, et al.
Publicado: (2020)

Assessment of Cross-Reactivity of Chimeric Trypanosoma cruzi Antigens with Crithidia sp. LVH-60A: Implications for Accurate Diagnostics
por: Santos, Emily F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_846m40cg3bifvvr1eo0og540iq